首页> 美国卫生研究院文献>Aging (Albany NY) >Identification and validation of the angiogenic genes for constructing diagnostic prognostic and recurrence models for hepatocellular carcinoma
【2h】

Identification and validation of the angiogenic genes for constructing diagnostic prognostic and recurrence models for hepatocellular carcinoma

机译:鉴定和验证血管生成基因用于构建肝细胞癌的诊断预后和复发模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Since angiogenesis has an indispensable effect in the development and progression of tumors, in this study we aimed to identify angiogenic genes closely associated with prognosis of HCC to establish diagnostic, prognostic, and recurrence models. We analyzed 132 angiogenic genes and HCC-related RNA sequence data from the TCGA and ICGC databases by Cox and least absolute shrinkage and selection operator (LASSO) regression, and identified four angiogenic genes (ENFA3, EGF, MMP3 and AURKB) to establish prognosis, recurrence and diagnostic models and corresponding nomograms. The prognostic and recurrence models were determined to be independent predictors of prognosis and recurrence (P < 0.05). And compared with the low-risk group, patients in the high-risk group had worse overall survival (OS) rates in training cohort (P < 0.001) and validation cohort (P < 0.001), and higher recurrence rates in training cohort (P<0.001) and validation cohort (P=0.01). The diagnostic models have been validated to correctly distinguish HCC from normal samples and proliferative nodule samples. Through pharmacological analysis we identified piperlongumine as a drug for targeting angiogenesis, and it was validated to inhibit HCC cell proliferation and angiogenesis via the EGF/EGFR axis.
机译:由于血管生成在肿瘤的发生和发展中具有不可或缺的作用,因此在本研究中,我们旨在鉴定与HCC预后密切相关的血管生成基因,以建立诊断,预后和复发模型。我们通过Cox和最小绝对收缩和选择算子(LASSO)回归分析了TCGA和ICGC数据库中的132个血管生成基因和HCC相关RNA序列数据,并确定了四个血管生成基因(ENFA3,EGF,MMP3和AURKB)以建立预后,复发和诊断模型以及相应的列线图。预后和复发模型被确定为预后和复发的独立预测因子(P <0.05)。与低风险组相比,高风险组的患者在训练队列(P <0.001)和验证队列(P <0.001)中的总生存率(P)较差,在训练队列中的复发率更高(P <0.001)和验证队列(P = 0.01)。诊断模型已经过验证,可以正确地区分HCC和正常样品以及增生性结节样品。通过药理分析,我们确定了哌隆定为靶向血管生成的药物,并已通过EGF / EGFR轴验证了它可以抑制HCC细胞增殖和血管生成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号